OMA102
OMA102 is in Phase 3 for female pattern hair loss, developed by EMS.
An undisclosed EMS oral tablet, registered for a Phase 3 in female pattern hair loss that has not started.
Nothing new since Feb 2024
- Developed by
- EMS
- Current phase
- Phase 3
- Mechanism
- Undisclosed
- Indications
- Female pattern hair loss
- Last public activity
- February 2024
- Copy last reviewed
- September 2026
- Record confidence
- Low
Large confirmatory trials. The last step before filing.
The sponsor has not said how it is supposed to work.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
A second Brazilian registrational programme in female pattern hair loss, from a different sponsor than Eurofarma's. The registry describes an oral tablet at 1 or 2 mg taken at bedtime, 504 women against placebo, with a planned start of January 2025; the record has not been updated since February 2024 and still reads 'not yet recruiting', so treat the phase as registered rather than under way. What the tablet is, EMS has not said.
Development history
- Phase 3
First Phase 3 trial on record: NCT05824065 — Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss
EMS · n=504 · January 2025
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- OMA102 in female pattern baldness — ClinicalTrials.gov
Related programmes
Other programmes in the register with the same approach.
Cite this page
Hair Pipeline, "OMA102 — development record", hairpipeline.com/pipeline/oma102